WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) granted stock options to five newly hired non-executive employees covering a total of 685,718 shares under its 2026 Inducement Equity Plan.
The awards were recently approved by the company’s compensation committee and issued as an inducement for employment in accordance with Nasdaq listing rules.
The options carry an exercise price of $1.68 per share, equal to the company’s closing stock price on March 31, 2026, and have a term of 10 years.
Vesting is structured with 25% of the options vesting after one year, with the remaining 75% vesting in equal monthly installments over the following 36 months.
The grants are subject to the terms of the inducement plan approved in March 2026 and individual award agreements.
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing treatments for cardiopulmonary diseases, including pulmonary arterial hypertension.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.